University of Nagasaki Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Nagasaki Japan (1949)

Organization Overview

First Clinical Trial
1998
NCT00145002
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Atsushi Kawakami | Department of Surgery Nagasaki University Graduate School of Biomedical Sciences | Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences | Institute of Tropical Medicine, Nagasaki University, Nagasaki | Nagasaki University | Nagasaki University Graduate School of Biomedical Science | Nagasaki University Hospital of Medicine and Dentistry | Tomoshi Tsuchiya | University of Nagasaki.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Constriction, Pathologic (Phase 1)

Edema (Phase 4)

Esophageal Stenosis (Phase 1)

Leishmaniasis (Phase 4)

Leishmaniasis, Visceral (Phase 4)

Leukemia (Phase 3)

Leukemia-Lymphoma, Adult T-Cell (Phase 3)

Leukemia, T-Cell (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Macular Edema (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Pneumococcal (Phase 4)

Schistosomiasis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 26